Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05644561 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
A Phase 3 study of Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 11
- Study locations
NCT05644561: Active Phase 3 study of Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals.
NCT05644561 is a Phase 3 study of Generalized Myasthenia Gravis and gMG that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 12 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05644561, a Phase 3 study of Generalized Myasthenia Gravis and gMG, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 11
- Study locations
Study Summary
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Conditions Studied
Interventions
- DRUG Ravulizumab
Study Locations (11)
Other
- Research Site - Milan
- Research Site - Roma
- Research Site - Torino
- Research Site - Itabashi-ku
- Research Site - Belgrade
- Research Site - Belgrade
- Research Site - Bern
California
- Research Site - Los Angeles
Massachusetts
- Research Site - Boston
North Carolina
- Research Site - Chapel Hill
Pennsylvania
- Research Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-06-24 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What the registry record for NCT05644561 still lists
NCT05644561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT05644561 lists 11 locations in 5 states (Other, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05644561 about?
NCT05644561 is a clinical study titled "Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)". The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
What is the current status of trial NCT05644561?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2023-06-24. Estimated completion is 2028-06-30.
What conditions does trial NCT05644561 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis, gMG.
What interventions are being tested in trial NCT05644561?
The interventions under investigation include: Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT05644561?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05644561 being conducted?
This trial has 11 study locations across California, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05644561's enrollment target sits among peer trials
12 22nd of 26 higher than 1 of 26 other Generalized Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RECRUITING · Phase 3
-
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI